2010
DOI: 10.1016/j.cct.2010.07.004
|View full text |Cite
|
Sign up to set email alerts
|

Rationale and design of a randomized trial to evaluate an evidence-based prescription drug label on actual medication use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
7

Relationship

4
3

Authors

Journals

citations
Cited by 23 publications
(14 citation statements)
references
References 41 publications
0
14
0
Order By: Relevance
“…24 Further study of the possible benefits, as well as risks of the UMS strategy is warranted, and evidence will soon be available from ongoing National Institutes of Health (NIH) and Agency for Healthcare Research and Quality (AHRQ) studies that are currently testing the UMS in actual use. 25–27 …”
Section: Discussionmentioning
confidence: 99%
“…24 Further study of the possible benefits, as well as risks of the UMS strategy is warranted, and evidence will soon be available from ongoing National Institutes of Health (NIH) and Agency for Healthcare Research and Quality (AHRQ) studies that are currently testing the UMS in actual use. 25–27 …”
Section: Discussionmentioning
confidence: 99%
“…A detailed account of the evidence supporting labeling changes is described in the 2008 IOM report and also by Shrank and colleagues. 10,25 The acceptability of the labeling was also supported by patient focus groups. 21 Label changes included dose instructions that were written in UMS form, stating when to take a medication using one of four daily standard time intervals (morning, noon, evening, bedtime).…”
Section: Interventionmentioning
confidence: 91%
“…A description of the trial is provided in greater detail in a previous publication. 25 The primary goal of the study was to determine whether the PCL strategy could improve 1) demonstrated proper use of prescribed drug regimens and 2) subsequent adherence compared to the current pharmacy standard. We hypothesized that this evidencebased label would improve proper use, and that it might also have a disproportionate benefit among those with limited literacy and English proficiency, but also among patients with greater regimen complexity.…”
Section: Methodsmentioning
confidence: 99%
“…The Table provides examples of common instructions provided in a way that implements the recommendations for patient-centred labels. [12][13][14]19 While there is work to be done to ensure patient-centred labels are implemented in Australia in a safe and effective manner, some aspects can be implemented immediately. Prescribers should, when possible, avoid 'as directed' and provide the indication.…”
Section: Guidelinesmentioning
confidence: 99%